全文获取类型
收费全文 | 219798篇 |
免费 | 20301篇 |
国内免费 | 15463篇 |
专业分类
耳鼻咽喉 | 1901篇 |
儿科学 | 2190篇 |
妇产科学 | 2979篇 |
基础医学 | 26526篇 |
口腔科学 | 3684篇 |
临床医学 | 30812篇 |
内科学 | 32935篇 |
皮肤病学 | 2226篇 |
神经病学 | 12393篇 |
特种医学 | 8223篇 |
外国民族医学 | 138篇 |
外科学 | 21723篇 |
综合类 | 35397篇 |
现状与发展 | 55篇 |
一般理论 | 19篇 |
预防医学 | 13152篇 |
眼科学 | 6695篇 |
药学 | 22721篇 |
194篇 | |
中国医学 | 12348篇 |
肿瘤学 | 19251篇 |
出版年
2024年 | 693篇 |
2023年 | 3558篇 |
2022年 | 9198篇 |
2021年 | 11526篇 |
2020年 | 8595篇 |
2019年 | 7539篇 |
2018年 | 8034篇 |
2017年 | 7085篇 |
2016年 | 6655篇 |
2015年 | 10251篇 |
2014年 | 12549篇 |
2013年 | 10692篇 |
2012年 | 16003篇 |
2011年 | 17948篇 |
2010年 | 10514篇 |
2009年 | 8182篇 |
2008年 | 11113篇 |
2007年 | 11087篇 |
2006年 | 11227篇 |
2005年 | 11322篇 |
2004年 | 6999篇 |
2003年 | 6612篇 |
2002年 | 5498篇 |
2001年 | 4935篇 |
2000年 | 5344篇 |
1999年 | 5686篇 |
1998年 | 3524篇 |
1997年 | 3497篇 |
1996年 | 2813篇 |
1995年 | 2606篇 |
1994年 | 2142篇 |
1993年 | 1376篇 |
1992年 | 1891篇 |
1991年 | 1595篇 |
1990年 | 1290篇 |
1989年 | 1091篇 |
1988年 | 1014篇 |
1987年 | 890篇 |
1986年 | 726篇 |
1985年 | 525篇 |
1984年 | 336篇 |
1983年 | 242篇 |
1982年 | 149篇 |
1981年 | 145篇 |
1980年 | 111篇 |
1979年 | 142篇 |
1978年 | 49篇 |
1977年 | 53篇 |
1975年 | 57篇 |
1974年 | 56篇 |
排序方式: 共有10000条查询结果,搜索用时 9 毫秒
31.
Tian-Yuan Xiong Fang-Yang Huang Qi Liu Yong Peng Yuan-Ning Xu Jia-Fu Wei 《Annals of medicine》2020,52(7):361-366
Abstract
Background
Comorbidities are commonly seen in patients with coronavirus disease 2019 (COVID-19), but the clinical implication is not yet well-delineated. We aim to characterize the prevalence and clinical implications of comorbidities in patients with COVID-19. 相似文献32.
Xue Yao Yan Zhang Jian Hao Hui-Quan Duan Chen-Xi Zhao Chao Sun Bo Li Bao-You Fan Xu Wang Wen-Xiang Li Xuan-Hao Fu Yong Hu Chang Liu Xiao-Hong Kong Shi-Qing Feng 《中国神经再生研究》2019,(3)
Ferroptosis is an iron-dependent novel cell death pathway. Deferoxamine, a ferroptosis inhibitor, has been reported to promote spinal cord injury repair. It has yet to be clarified whether ferroptosis inhibition represents the mechanism of action of Deferoxamine on spinal cord injury recovery. A rat model of Deferoxamine at thoracic 10 segment was established using a modified Allen's method. Ninety 8-week-old female Wistar rats were used. Rats in the Deferoxamine group were intraperitoneally injected with 100 mg/kg Deferoxamine 30 minutes before injury. Simultaneously, the Sham and Deferoxamine groups served as controls. Drug administration was conducted for 7 consecutive days. The results were as follows:(1) Electron microscopy revealed shrunken mitochondria in the spinal cord injury group.(2) The Basso, Beattie and Bresnahan locomotor rating score showed that recovery of the hindlimb was remarkably better in the Deferoxamine group than in the spinal cord injury group.(3) The iron concentration was lower in the Deferoxamine group than in the spinal cord injury group after injury.(4) Western blot assay revealed that, compared with the spinal cord injury group, GPX4, xCT, and glutathione expression was markedly increased in the Deferoxamine group.(5) Real-time polymerase chain reaction revealed that, compared with the Deferoxamine group, mRNA levels of ferroptosis-related genes Acyl-CoA synthetase family member 2(ACSF2) and iron-responsive element-binding protein 2(IREB2) were up-regulated in the Deferoxamine group.(6) Deferoxamine increased survival of neurons and inhibited gliosis. These findings confirm that Deferoxamine can repair spinal cord injury by inhibiting ferroptosis. Targeting ferroptosis is therefore a promising therapeutic approach for spinal cord injury. 相似文献
33.
34.
35.
36.
目的:肌少症对老年肝癌术后恢复及预后的影响。方法:选取2015年1月至2017年12月收治的114例老年肝癌,根据有无合并肌少症,分为肌少症组(n=35)和非肌少症组(n=79)。比较两组患者的术后恢复及生存情况。结果:肌少症组总并发症发生率、住院时间和30 d再入院率均高于对照组,差异均有统计学意义(P<0.05)。肌少症组中位生存时间为25.9个月,1年、2年、3年累积总生存率为74.3%、51.1%、24.5%,而非肌少症组中位生存时间为35.7个月,1年、2年、3年累积总生存率为87.3%、75.6%、49.4%,差异有统计学意义(P=0.004)。单因素分析结果显示,老年肝癌术后预后与Charlson合并症指数(CCI)、肌少症、巴塞罗那分期(BCLC)、甲胎蛋白、肿瘤大小、肿瘤个数、肿瘤分化程度、微血管侵犯(MVI)相关(P<0.05)。Cox多因素分析结果显示,CCI、肌少症、BCLC分期、肿瘤个数、MVI是老年肝癌术后预后的独立危险因素(P<0.05)。结论:肌少症会增加老年肝癌患者术后并发症发生率,延长住院时间,影响术后恢复,同时也会降低总生存率。 相似文献
37.
38.
39.
40.
The objective of this study was to investigate the absorption behavior of chikusetsusaponin IVa (CHS‐IVa) in the rat intestine using single‐pass intestinal perfusion (SPIP) and to classify CHS‐IVa into the biopharmaceutics classification system (BCS). The equilibrium solubility of CHS‐IVa was determined by the shaker method. The absorption mechanism of CHS‐IVa in the intestine was studied by comparing the Peff of different concentrations of CHS‐IVa. The intestinal site dependence of CHS‐IVa absorption was studied by comparing the Peff of the same concentration of CHS‐IVa in different intestinal segments. The relationship between CHS‐IVa and intestinal efflux protein was studied by perfusion with an efflux protein inhibitor. The permeability of CHS‐IVa was investigated by comparing the Peff of CHS‐IVa and the reported value. The solubility of CHS‐IVa over the pH range 1.0–7.5 was 14.4 ± 0.29 to 16.9 ± 0.34 mg/ml. The Peff of CHS‐IVa in the duodenum was 1.76 × 10?3 to 2.00 × 10?3 cm/min. The Peff of CHS‐IVa in the jejunum was 1.26 × 10?3 to 1.39 × 10?3 cm/min. The Peff of CHS‐IVa in the ileum was 1.25 × 10?3 to 1.31 × 10?3 cm/min. The Peff of CHS‐IVa in the colon was 1.02 × 10?3 to 1.08 × 10?3 cm/min. There was no statistical difference of the Peff in the four segments at different CHS‐IVa concentrations. The Peff of CHS‐IVa (0.07, 0.7 and 7.0 mg/ml) were all notably smaller than the reported Peff (3.00 × 10?3 cm/min) in the jejunum. The Peff of CHS‐IVa was not influenced by verapamil (P‐gp inhibitor), indomethacin (MRP inhibitor) and pantoprazole (BCRP inhibitor). CHS‐IVa was classified as high solubility, low permeability and BCS III. The main absorptive tracts were the upper intestinal tracts and the rank order of intestinal permeability was duodenum > jejunum ≈ ileum > colon. The transport mechanism of CHS‐IVa in all intestinal segments might be primarily passive transport. CHS‐IVa was not a substrate of P‐gp, MRP and BCRP. 相似文献